Download Gene Section CDC25A (cell division cycle 25A) Atlas of Genetics and Cytogenetics

Survey
yes no Was this document useful for you?
   Thank you for your participation!

* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project

Document related concepts

Monoclonal antibody wikipedia , lookup

RNA-Seq wikipedia , lookup

Signal transduction wikipedia , lookup

Two-hybrid screening wikipedia , lookup

Biochemistry wikipedia , lookup

Gene therapy of the human retina wikipedia , lookup

Endogenous retrovirus wikipedia , lookup

Paracrine signalling wikipedia , lookup

Artificial gene synthesis wikipedia , lookup

Point mutation wikipedia , lookup

Gene regulatory network wikipedia , lookup

Secreted frizzled-related protein 1 wikipedia , lookup

Vectors in gene therapy wikipedia , lookup

Transcript
Atlas of Genetics and Cytogenetics
in Oncology and Haematology
OPEN ACCESS JOURNAL AT INIST-CNRS
Gene Section
Review
CDC25A (cell division cycle 25A)
Dipankar Ray, Hiroaki Kiyokawa
Department of Mol. Pharmacol & Biol. Chem, Northwestern University, Chicago, IL 60611, USA (DR,
HK); Robert H. Lurie Compre. Cancer Center, Northwestern University, Chicago, IL 60611, USA (HK)
Published in Atlas Database: February 2008
Online updated version: http://AtlasGeneticsOncology.org/Genes/CDC25AID40004ch3p21.html
DOI: 10.4267/2042/38593
This work is licensed under a Creative Commons Attribution-Non-commercial-No Derivative Works 2.0 France Licence.
© 2008 Atlas of Genetics and Cytogenetics in Oncology and Haematology
reported, CDC25A1 and A2. The transcript variant
CDC25A2, has a deletion of 120 nucleotide (exon 6)
resulted in a protein having truncation of 40 amino acid
(between amino acid 143-182). However, both the Nterminal and C-terminal end of the protein is the same
in both splice variant.
Identity
Hugo: CDC25A
Other names: CDC25A2
Location: 3p21
Local order: The gene is located telomeric to CAMP
(cathelicidin antimicrobial peptide) and centromeric to
LOC729349 (a pseudogene similar to 60S ribosomal
protein L17 (L23)). The gene starts at 48,173,672 bp
from pter and ends at 48,204,805 bp from pter with a
total size of 31,133 bases.
Protein
Description
The full length CDC25A protein consists of 524 amino
acids with an estimated molecular weight of 59 kDa.
The other reported isoform CDC25A2, consists of 484
amino acids with a molecular weight of 54.4 kDa. Both
the isoforms have the same N- and C-terminal end, thus
expected to have similar catalytic activity. The Nterminal regulatory domain contains several
phosphorylation sites and show low sequence
homology between CDC25 family members, whereas
C-terminal end has conserved Rhodanese homology
domain containing the active site cysteine. The
catalytic site contain the CX5R motif (C= cysteine; X=
any amino acid; R= arginine) common to all protein
tyrosine phosphatases.
DNA/RNA
Description
CDC25A is about 31.13 kb located on the short (p) arm
of chromosome 3, in the centromere-to-telomere
orientation. The gene has 15 exons and the start codon
is located at the end of exon 1 and stop codon in the
beginning of exon 15.
Transcription
The CDC25A transcript is 3704 bp in length. So far
there are two major transcript variant have been
Genomic organization of human CDC25A gene on chromosome 3 p-ter.
Atlas Genet Cytogenet Oncol Haematol. 2008;12(6)
421
CDC25A (cell division cycle 25A)
Ray D, Kiyokawa H
Domains of different isoforms of CDC25A (A1 and A2). The splice variant A2 lacks an in-frame exon (exon 6) encoding 40 amino acids
(amino acid 143-182), however, have the same N- and C-termini compared to isoform A1. The approx. molecular weight of each isoform
is mentioned in parenthesis.
CDC25A initially believed to be a nuclear protein. But
using fluorescence loss in photobleaching (FLIP) the
more dynamic nuclear-cytosolic shuttling of CDC25A
localization have been reported. At the very N-terminus
end between amino acid 38-59, the nuclear export
sequence (NES) is located, whereas between amino
acid 272-294, a bipartite nuclear localization signal
(NLS) proved to be important for its nuclear
localization.
mainly due to post-translation stabilization as oppose to
gene amplification or transcriptional upregulation.
- CDC25A protein level is important for oncogeneinduced transformation and mouse mammary tumor
virus
(MMTV)-neu/ras
induced
mammary
tumorigenesis.
- During early cell cycle progression glycogen synthase
kinase 3-beta (GSK-3beta) can phosphorylate and
degrade CDC25A, thus maintain the lower cellular
levels of CDC25A. Interestingly, the same report
showed that overproduction of CDC25A in human
cancers is correlated to the inactivation of GSK-3beta.
- It is an inhibitor of apoptosis by inhibiting apoptosis
signal-regulating kinase 1 (ASK1).
- CDC25A plays an important role in spermatogenesis
as decreased transcript level of Cdc25A is correlated
with spermatogenic failure and failed sperm retrieval in
infertile men.
Function
Homology
- It is a member of the M-phase inducer (MPI)
phosphatase family protein, which not only regulates
mitotic progression by activating mitotic CDKs in a
dosage-dependent manner, it is also equally important
for G1 to S-phase transition.
- During G1 to S transition, it activates CDK2 by
removing two inhibitory phosphates on residues
threonine 14 and tyrosine 15. During G2/M transition
CDC25A similarly regulates the activity of CDK1
(CDC2).
- It is an important checkpoint protein in response to
damage by ionizing radiation (IR), ultraviolet light
(UV), replication inhibitor and by various DNA
damaging agents. In response to DNA damage,
CDC25A
undergoes
CHK1/CHK2
-mediated
phosphorylation followed by ubiquitination-dependent
degradation leading to growth arrest in a p53 independent manner.
- CDC25A is essential for early embryonic
development as Cdc25A-null mice die in utero by
embryonic day 7.
- CDC25A is overexpressed in a variety of human
cancers including breast, esophageal, gastric, lung,
thyroid, head and neck cancers and lymphomas.
CDC25A overexpression at least in breast cancer is
CDC25A gene is highly conserved among mammals
(99% homology with Chimpanzee; 90% with dog;
about 86% with rat and about 85% with mouse). In
mammals, CDC25A has two orthologs, CDC25B and
CDC25C. Among them, the N-terminal regulatory
region show low sequence homology (20-25%
identity), however, the C-terminal catalytic region is
quite conserved with about 64% homology with
CDC25B and about 58% homology to CDC25C.
Expression
CDC25A is expressed early during embryonic stages
and in adults it is expressed in a variety of normal cells
and tissues. CDC25A is a highly expressed gene in a
variety of human cancers including breast, esophageal,
gastric, lung, thyroid, head and neck cancers and also in
high grade lymphomas.
Localisation
Atlas Genet Cytogenet Oncol Haematol. 2008;12(6)
Mutations
Note: Gene mutation or amplification is not commonly
reported for CDC25A. A naturally occurring point
mutation (C to A) of mouse Cdc25A gene has been
reported where Histidine 128 (CAC) has been
converted to Glutamine (CAA). This change caused an
increase in CDC25A phosphatase activity and thereby
affected erythropoiesis in mice only under certain
genetic background.
Implicated in
Note: CDC25A is overexpressed in a variety of human
cancers including breast, hepatocellular, ovarian,
colorectal, esophageal, head and neck cancer and also
in non-Hodgkin lymphoma.
422
CDC25A (cell division cycle 25A)
Ray D, Kiyokawa H
Mailand N, Falck J, Lukas C, Syljuâsen RG, Welcker M, Bartek
J, Lukas J. Rapid destruction of human Cdc25A in response to
DNA damage. Science 2000;288(5470):1425-1429.
Breast cancer
Note: - In about 47% of early (T1) stage breast cancer
patients CDC25A is reported to be overexpressed.
- Although the mechanism of CDC25A upregulation in
human patients is not yet clear, however, in some
breast cancer cell lines it was reported that CDC25A
overexpression is mainly due to increased protein
stability as oppose to gene amplification or
transcriptional upregulation.
- In mice, overexpression of CDC25A alone in
mammary gland using mouse mammary tumor virus
(MMTV) promoter, is not sufficient to induce
mammary tumorigenesis. However, such mammary
specific overexpression of CDC25A does cooperate
with HER2/neu-ras signaling to form more aggressive
tumors with enhanced genomic instability.
- In contrast, hemizygous loss of Cdc25A in mice
protected them significantly from MMTV-neu/rasinduced mammary tumorigenesis, possibly by
restricting precancerous cell proliferation and also by
enhancing G2-checkpoint response. Thus the protein
level of CDC25A is crucial for the initiation and/or
progression of breast tumorigenesis in mice.
Prognosis
Overexpression of CDC25A is correlated with more
aggressive breast cancer with poor prognosis.
Cytogenetics
CDC25A overexpression in MMTV-CDC25A;
MMTV-neu double transgenic mice caused faster
tumor growth as compared to MMTV-neu single
transgenic mice. Importantly, such CDC25A
overexpressing tumor cells displayed miscoordination
of S phase and mitosis, and had severe genomic
instability as evidenced by aneuploidy and deletion of
fragile chromosomal regions (e.g., telomeric region of
chromosome 4, which is homologous to human
chromosome 1p31-36, a hotspot for several human
cancers including breast cancer).
Wegener S, Hampe W, Herrmann D, Schaller HC. Alternative
splicing in the regulatory region of the human phosphatases
CDC25A and CDC25C. Eur J Cell Biol 2000;79:810-815.
Bartek J, Lukas J. Mammalian G1- and S-phase checkpoints in
response to DNA damage. Curr Opin Cell Biol 2001;13(6):73847. (Review).
Wang Z, Southwick EC, Wang M, Kar S, Rosi KS, Wilcox CS,
Lazo JS, Carr BI. Involvement of Cdc25A phosphatase in
Hep3B hepatoma cell growth inhibition induced by novel K
vitamin analogs. Cancer Res 2001;61(19):7211-7216.
Zou X, Tsutsui T, Ray D, Blomquist JF, Ichijo H, Ucker DS,
Kiyokawa H. The cell cycle-regulatory CDC25A phosphatase
inhibits apoptosis signal-regulating kinase 1. Mol Cell Biol
2001;21(14):4818-4828.
Mailand N, Podtelejnikov AV, Groth A, Mann M, Bartek J,
Lukas J. Regulation of G(2)/M events by Cdc25A through
phosphorylation-dependent modulation of its stability. EMBO J
2002;21(21):5911-5920.
Melkun E, Pilione M, Paulson RF. A naturally occurring point
substitution in Cdc25A, and not Fv2/Stk, is associated with
altered cell-cycle status of early erythroid progenitor cells.
Blood 2002;100(10):3804-3811.
Löffler H, Syljuǻsen RG, Bartkova J, Worm J, Lukas J, Bartek
J. Distinct modes of deregulation of the proto-oncogenic
Cdc25A phosphatase in human breast cancer cell lines.
Oncogene 2003;22(50):8063-8071.
Xiao Z, Chen Z, Gunasekera AH, Sowin TJ, Rosenberg SH,
Fesik S, Zhang H. Chk1 mediates S and G2 arrests through
Cdc25A degradation in response to DNA-damaging agents. J
Biol Chem 2003;278(24):21767-21773.
Xu X, Yamamoto H, Sakon M, Yasui M, Ngan CY, Fukunaga
H, Morita T, Ogawa M, Nagano H, Nakamori S, Sekimoto M,
Matsuura N, Monden M. Overexpression of CDC25A
phosphatase is associated with hypergrowth activity and poor
prognosis of human hepatocellular carcinomas. Clin Cancer
Res 2003;9(5):1764-1772.
Källström H, Lindqvist A, Pospisil V, Lundgren A, Rosenthal
CK. Cdc25A localisation and shuttling: characterisation of
sequences mediating nuclear export and import. Exp Cell Res
2005;303:89-100.
Kar S, Wang M, Yao W, Michejda CJ, Carr BI. PM-20, a novel
inhibitor of Cdc25A, induces extracellular signal-regulated
kinase 1/2 phosphorylation and inhibits hepatocellular
carcinoma growth in vitro and in vivo. Mol Cancer Ther
2006;5(6):1511-1519.
Hepatocellular carcinoma
Note: Different CDC25 inhibitor (such as vitamin K
analog Cpd 5; phenyl maleimide compound PM-20; 2Methoxyestadiol, a physiological metabolite of
estrogen) are capable of inhibiting the hepatocellular
carcinoma growth both in vitro and in vivo.
Prognosis
CDC25A overexpression is associated with poor
prognosis of hepatocellular carcinoma.
Boutros R, Lobjois V, Ducommun B. CDC25 phosphatases in
cancer cells: key players? Good targets?. Nat Rev 2007;7:495507. (Review).
Ray D, Kiyokawa H. CDC25A levels determine the balance of
proliferation
and
checkpoint
response.
Cell
Cycle
2007;6(24):3039-3042. (Review).
Ray D, Terao Y, Fuhrken PG, Ma ZQ, DeMayo FJ, Christov K,
Heerema NA, Franks R, Tsai SY, Papoutsakis ET, Kiyokawa
H. Deregulated CDC25A expression promotes mammary
tumorigenesis with genomic instability. Cancer Res
2007;67(3):984-991.
References
Ray D, Terao Y, Nimbalkar D, Hirai H, Osmundson EC, Zou X,
Franks R, Christov K, Kiyokawa H. Hemizygous disruption of
Cdc25A inhibits cellular transformation and mammary
tumorigenesis in mice. Cancer Res 2007;67(14):6605-6611.
Galaktionov K, Beach D. Specific activation of cdc25 tyrosine
phosphatases by B-type cyclins: evidence for multiple roles of
mitotic cyclins. Cell 1991;67(6):1181-1194.
Kang T, Wei Y, Honaker Y, Yamaguchi H, Appella E, Hung
MC, Piwnica-Worms H. GSK-3 beta targets Cdc25A for
ubiquitin-mediated proteolysis, and GSK-3 beta inactivation
Demetrick D, Beach DH. Chromosome mapping of human
CDC25A and CDC25B phosphatases. Genomics 1993;18:144147.
Atlas Genet Cytogenet Oncol Haematol. 2008;12(6)
423
CDC25A (cell division cycle 25A)
Ray D, Kiyokawa H
correlates with Cdc25A overproduction in human cancers.
Cancer Cell 2008;13(1):36-47.
This article should be referenced as such:
Ray D, Kiyokawa H. CDC25A (cell division cycle 25A). Atlas
Genet Cytogenet Oncol Haematol.2008;12(6):421-424.
Kar S, Wang M, Carr BI. 2-Methoxyestradiol inhibits
hepatocellular carcinoma cell growth by inhibiting Cdc25 and
inducing cell cycle arrest and apoptosis. Mol Chemother
Pharmacol 2008 Oct;62(5):831-40.
Atlas Genet Cytogenet Oncol Haematol. 2008;12(6)
424